AOD-9604 vs Retatrutide
A modified fragment of human growth hormone that targets fat cells for breakdown without affecting blood sugar or muscle growth—your metabolism's precision tool.
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
AOD-9604
300–400 mcg
Retatrutide
4–8 mg
Frequency
AOD-9604
Once daily
Retatrutide
Once weekly
Administration
AOD-9604
Subcutaneous injection
Retatrutide
Subcutaneous injection
Cycle length
AOD-9604
8-12 weeks
Retatrutide
12+ weeks
Onset speed
AOD-9604
Gradual (3-4 weeks)
Retatrutide
Moderate (1-2 weeks)
Evidence level
AOD-9604
Moderate human trials (Phase 1-2)
Retatrutide
Moderate human trials (Phase 1-2)
Benefit ratings
Fat Targeting
Safety Profile
Joint Support
Weight Loss Power
Metabolic Health
Appetite Control
Compound specifications
AOD-9604
Molecular formula
C78H123N23O23S2
Molecular weight
1815.1 g/mol
Half-life
~3-4 minutes (plasma)
Bioavailability
High (subcutaneous)
CAS number
221231-10-3
Retatrutide
Molecular formula
C221H342N46O68
Molecular weight
4731 g/mol
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS number
2381089-83-2
Dosing compared
AOD-9604
Subcutaneous
250 mcg
Once daily · 2-4 weeks
AOD9604 is a research peptide and not an approved medicine. Doses around 250 mcg under the skin are a common starting point in practice. In a human trial the most effective amount was about 1 mg per day. [1][5]
300-400 mcg
Once daily · 8-12 weeks
A commonly used daily amount in practice. The largest human study found benefit up to about 1 mg/day with no extra gain from higher doses. [1][5]
500 mcg
Once daily · 8-12 weeks
A higher amount sometimes used in practice. Going above roughly 1 mg/day did not improve results in the human trial. [1][5]
Retatrutide
Subcutaneous
Weeks 1-4
2 mg
Once weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)
Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
Maintenance after titration
4-8 mg
Once weekly · Maintenance after titration
Mid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
Maintenance (highest studied)
12 mg
Once weekly · Maintenance (highest studied)
Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Best suited for
AOD-9604
Targeted Fat Loss
AOD-9604 shines when you want to target stubborn fat deposits. It works by mimicking how growth hormone breaks down fat, but without the side effects of actual HGH. Think of it as a smart missile that targets fat cells specifically.
Body Recomposition
Perfect for those who want to lose fat while maintaining muscle. Unlike many fat loss compounds, AOD-9604 doesn't affect muscle tissue or mess with your blood sugar levels—it's laser-focused on fat metabolism.
Metabolic Enhancement
Ideal for boosting your metabolism naturally. AOD-9604 increases fat oxidation (your body's ability to burn fat for fuel) without the jittery stimulant effects of caffeine or other thermogenics.
Joint Health Support
Emerging research shows AOD-9604 may help repair cartilage and support joint health. Studies in osteoarthritis models show it can reduce cartilage damage, making it a dual-purpose peptide for active individuals.
Metabolically Safe Fat Loss
Unlike many weight loss compounds, AOD-9604 doesn't raise blood sugar, doesn't affect insulin, and doesn't stimulate cell growth. It's one of the gentlest approaches to enhancing fat metabolism available.
Retatrutide
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Side effects
AOD-9604
Common
- Injection site reactions
- Mild headache
- Flushing or warmth
Uncommon
- Fatigue
- Dizziness
Serious
- Allergic reaction
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Safety & evidence
AOD-9604
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved
Safety overview
AOD-9604 has been studied in multiple human clinical trials involving thousands of participants. The safety profile is notably clean—it doesn't affect blood sugar, insulin levels, or cause the typical side effects of growth hormone. Phase 2 trials showed it was well-tolerated even at doses higher than typically used. The most common side effects are mild and injection-site related.
Contraindications
- Pregnancy or breastfeeding
- Active cancer or history of cancer
- Known allergy to growth hormone-derived peptides
- Children and adolescents
Retatrutide
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Which is right for you?
Choose AOD-9604 if...
- Fat loss
- Body composition improvement
- Metabolic support
- Joint health support
Choose Retatrutide if...
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization